Authors

Deb Nevins is the Chief Marketing & Strategy Officer at POCN Group. POCN Group, an IQVIA business, is the life-sciences engagement division of POCN. The organization combines verified NP and PA identity, behavioral and attitudinal insight, and peer-led education to help healthcare companies identify, understand, and engage these clinicians with precision and credibility. Drawing on over a decade of NP/PA expertise, POCN Group translates real-world clinician behavior and mindset into actionable brand strategy, compliant activation, and measurable impact across the product lifecycle.

The CEO of TransCelerate BioPharma Inc. She has been part of the organization since its inception in 2012 and has more than 20 years of experience leading initiatives in large pharma and biotech companies across regulatory, clinical, and manufacturing. Chang holds a dual degree from the University of Pennsylvania and The Wharton School.

Senior vice president of healthcare content at Ruder Finn. Previously, Wiese held various positions in the field of communications, including copy director at Burson from 2022 to 2025 and associate director of creative copy at Real Chemistry from 2020 to 2022. Wiese earned a bachelor’s degree in communication and media studies from Hobart and William Smith Colleges and a master’s degree in public relations from the S.I. Newhouse School of Public Communications at Syracuse University.

Content director at The Vanguard Network, an advisory organization that connects industry leaders through in-person forums and virtual exchanges. His work has appeared in publications such as The Wall Street Journal and Financial Times.

Is vice president, offering development within IQVIA’S global commerce offering business responsible for global launch excellence. Over the past 25 years, she has worked with some of the world’s most successful brands across both the pharma and CPG industries in Europe, the Americas, and Southeast Asia.